Patient Perspectives on Switching From Infliximab to Infliximab‐dyyb in Patients With Rheumatologic Diseases in the United States

ACR Open Rheumatology
doi 10.1002/acr2.1007
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Efficacious Transition From Reference Infliximab to Biosimilar Infliximab in Clinical Practice

International Journal of Rheumatic Diseases
Rheumatology
2019English

Polyarthritis Flare in Patient With Ankylosing Spondylitis Treated With Infliximab

Reumatismo
Rheumatology
2011English

Switching Maintenance Infliximab Therapy to Biosimilar-Infliximab Does Not Lead to Significant Changes in Health-Related Quality of Life and Clinical Outcomes in Inflammatory Bowel Disease Patients

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Serum Infliximab Level in an Infant Delivered From a Mother With Psoriatic Arthritis Receiving Infliximab

Journal of Dermatology
DermatologyMedicine
2019English

Autoimmune Hepatitis Associated With Infliximab in a Patient With Psoriatic Arthritis

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2005English

Efficacy of Infliximab Biosimilars in Patients With Crohn's Disease

The Lancet
Medicine
2017English

Letter: Is There a Role for Infliximab Biosimilar in Patients With Inflammatory Bowel Disease With Secondary Loss of Response to Infliximab Innovator?

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

THU0218 the Efficacy and Drug Survival of the Biosimilar Infliximab (CT-P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results From the Turkbio Registry

2018English

Ramsay Hunt Syndrome in a Patient With Rheumatoid Arthritis After Treatment With Infliximab

Case Reports in Rheumatology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy